Text Size
Santen Global

2020 IR News

RSS

IR News

Santen to Present Latest Data on Omidenepag Isopropyl and Microshunt at AAO 2020 Virtual
Santen Reports the 2nd Quarter Fiscal 2020 Consolidated Performance
Santen releases LENTIS Comfort Toric in Japan, a multifocal IOL covered under the Japanese health insurance program for cataract patients with astigmatism
Santen, JBFA and IBF Foundation Form Long-term Partnership for an Inclusive Society ~An innovative, 10-year partnership agreement that aims to achieve long-term stability of sports management for the advancement of diversity and inclusion in our society~
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa and Rocklatan in Japan and Several Other Asian Countries
Notice on the Establishment of Holding Company in China
Santen and Orbis International Announce Long-term Partnership to Tackle the Increasing Burden of Eye Diseases
Santen and U.S. Ophthalmic Company Eyevance Enters into Share Purchase Agreement
Notice of Corporate Officer Appointments
Santen Reports the 1st Quarter Fiscal 2020 Consolidated Performance
Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen Introduces its New Corporate Brand Name Notation and Corporate Slogan Aiming to Grow on a Globally, Going beyond the Pharmaceutical Industry
Announcement of New Vision Aiming to Resolve Social Issues Related to the Eye Health of People around the World
Santen Announces U.S. FDA Acceptance of Premarket Approval (PMA) Application for DE-128 (MicroShunt) for Review
Corporate Governance Report
Santen and Singapore's Health-tech Start-up, Plano Form a Strategic Alliance to Tackle the Global Burden of Myopia
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen and Orbis International Join Forces to Expand Access to Training for Eye Care Professionals through Telemedicine Platform
Providing Eye Care Information to Resolve Problems Caused by Excessive Screen Time
Bayer Yakuhin and Santen launch 'EYLEA Intravitreal Injection KIT 40mg/mL', pre-filled syringe of intravitreal VEGF Inhibitor EYLEA
Notice of Board of Director and Corporate Auditor Nominations
Santen Reports Fiscal 2019 Consolidated Performance
Santen and jCyte Conclude an Exclusive Licensing Contract in Japan, Asia and Europe for the jCell Therapy Program for Retinitis Pigmentosa
Santen, Together with Nonprofit Organization, Japan Blind Football Association, to Support People with Visual Impairments Facing the COVID-19 Pandemic
Santen Introduces Eco-Friendly Biomass Plastic Eyedrop Bottles
Intravitreal VEGF Inhibitor EYLEA approved as a Treatment of Neovascular Glaucoma (NVG), its fifth indication
Notice of Corporate Officer Appointments
Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020)
Notice of personnel change
Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices
Santen Reports the 3rd Quarter Fiscal 2019 Consolidated Performance
Santen Pharmaceutical Selected as Title Sponsor of IBSA Blind Football World Grand Prix 2020!
Santen Pharmaceutical Signs Partnership Agreement with ITU Supporting ITU and WHO initiative 'Be He@lthy, Be Mobile' in Ophthalmology
Santen Announces the Construction of China Second Plant
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved